chemoimmunotherapy alone AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

AstraZeneca’s (AZN) Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for the treatment of adult patients with previously ...

Calquence combo reduced disease progression or death risk by 27% in untreated mantle cell lymphoma. Learn how to trade volatility during Q1 earnings season, live with Matt Maley on Wednesday ...

Calquence plus Venclexta, with or without Gazyva, significantly improved progression-free and overall survival in untreated CLL patients compared to chemoimmunotherapy. The study showed a higher ...

The recommendation, announced today, is based on the ECHO Phase III trial results, which showed a notable improvement in progression-free survival when Calquence was used in combination with ...

The recommendation, announced today, is based on the ECHO Phase III trial results, which showed a notable improvement in progression-free survival when Calquence was used in combination with ...